Clinical Trial Results:
An 8-week exploratory, double-blind, placebo controlled, randomized trial :
Evaluation of the efficacy and safety of levetiracetam up to 3000 mg/day (250-500 mg oral tablets in b.i.d. administration) on neuroleptic-induced tardive dyskinesia in subjects with stable axis I psychiatric disorder, aged from at least 18 years to 80 years.
Summary
|
|
EudraCT number |
2004-001302-27 |
Trial protocol |
HU DE |
Global completion date |
29 Dec 2005
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 Dec 2016
|
First version publication date |
23 Dec 2016
|
Other versions |
|
Summary report(s) |
Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.